**Synthesis of PF-06650833**

**Significance:** PF-06650833 is an interleukin-4 receptor associated kinase (IRAK-4) inhibitor that is of interest for the treatment of inflammatory disorders such as rheumatoid arthritis. A significant challenge in the large-scale synthesis of PF-06650833 was the construction of lactam **I** with its three contiguous stereogenic centers.

**Comment:** The preparation of lactam **I** from **E** was achieved by the highly diastereoselective oxidation of enolate **E** to **F** with lithium tert-butylperoxide in a flow process (Organ. Process Res. Dev. 2018, 22, 707, see also Synfacts 2019, 15, 328, this issue). Thereafter activation of **F** by reaction with nonafluorobutanesulfonyl fluoride allowed $\text{S}_{\text{N}}\text{2}$ displacement by fluoride ion in a single step, without need for the isolation of the intermediate sulfonate ester **G**. This route provided PF-06650833 in batches of greater than 30 kg at a time.